Skip to the main content

Acta clinica Croatica, Vol. 56. No. 1., 2017.

Review article

https://doi.org/10.20471/acc.2017.56.01.20

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies

Vibor Milunović orcid id orcid.org/0000-0003-0069-6688 ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia; Lombardi Comprehensive Cancer Centre, Georgetown University, Washington D.C., USA
Martina Bogeljić Patekar ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia
Karla Mišura Jakubac ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia
Inga Mandac Rogulj ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia
Delfa Radić-Krišto ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia
Ana Planinc-Peraica ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Slobodanka Ostojić Kolonić ; Division of Hematology, Merkur University Hospital, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia

Full text: english pdf 199 Kb

page 143-156

downloads: 1.064

cite

Abstract

Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present data on the use of rituximab in the treatment of follicular lymphoma (FL). We will focus on rituximab maintenance strategies in the first and second line treatment. Th is approach has improved the outcome in FL patients with better progression-free survival in all patients and better overall survival in relapsed setting. Regardless of good results, this strategy has generated controversies in medical community in the range from the lack of overall survival benefit in first line setting, adverse effects of possible overtreatment and toxicities to its unknown role in the era of novel agents. The existing data suggest that rituximab maintenance should be a rational therapeutic option for all patients with FL responding to first line therapy and transplant-ineligible patients responding to reinduction.

Keywords

Rituximab; Lymphoma, non-Hodgkin – therapy; Lymphoma, follicular; Maintenance chemotherapy; Treatment outcome

Hrčak ID:

184430

URI

https://hrcak.srce.hr/184430

Publication date:

1.3.2017.

Article data in other languages: croatian

Visits: 2.941 *